trending Market Intelligence /marketintelligence/en/news-insights/trending/4zelifwpkvr1hhqjgelvbq2 content esgSubNav
In This List

Axovant Sciences prices $30M common stock offering

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Axovant Sciences prices $30M common stock offering

Axovant Sciences Ltd. priced an underwritten public offering of 30 million common shares at $1 apiece to raise $30 million in gross proceeds.

The company granted the underwriters an option to buy up to an additional 4.5 million shares.

Axovant expects to close the offering Dec. 18, subject to customary closing conditions.

Jefferies and Guggenheim Securities are acting as joint book-running managers. JMP Securities is the lead manager, and H.C. Wainwright & Co. is the co-manager for the offering.

Axovant Sciences is a clinical-stage gene therapy company that develops treatments for debilitating neurological and neuromuscular diseases.